Quick Summary
Click here for Price and Turnaround Time
Phenotype: Progressive retinal atrophy is characterized by bilateral degeneration of the retina resulting in progressive vision loss leading to total blindness. Clinical signs of PRA1 appear around 6 years of age. Clinical symptoms of PRA2 appear around 4 years of age.
Mode of Inheritance: Autosomal recessive
Alleles:
N = Normal
PRA1 = Golden Retriever progressive retinal atrophy (variant 1)
PRA2 = Golden Retriever progressive retinal atrophy (variant 2)
Breeds appropriate for testing: Golden Retriever, Golden Doodle, Labrador Retriever
Explanation of Results:
- Dogs with N/N genotype are not expected to develop either of these two forms of Golden Retriever progressive retinal atrophy and cannot transmit these progressive retinal atrophy variants to their offspring.
- Dogs with N/PRA1 or N/PRA2 genotype are not expected to develop either of these two forms of Golden Retriever progressive retinal atrophy, but are carriers. They may transmit a Golden Retriever progressive retinal atrophy variant to 50% of their offspring. Matings between two carriers of the same variant (e.g. N/GR_PRA1 x N/GR_PRA1) are predicted to produce 25% of puppies affected by that form of progressive retinal atrophy. Matings between two carriers of the different variants (N/GR_PRA1 x N/GR_PRA2) will not produce affected offspring.
- Dogs with PRA1/PRA1 or PRA2/PRA2 are expected to develop progressive retinal atrophy. They will transmit respective progressive retinal atrophy variants to all of their offspring.
Results of this test can be submitted to the OFA (Orthopedic Foundation for Animals)
Golden Retriever Health Panel
$130 per animal
More than 20 mutations have been identified that result in canine progressive retinal atrophy (PRA). The condition is characterized by bilateral degeneration of the retina resulting in progressive vision loss leading to total blindness. Golden Retrievers are affected by more than one form of PRA with mutations in three distinct genes having been identified. Two of such mutations are known as PRA1 and PRA2. PRA1 results from a mutation in the SLC4A3 gene and accounts for over 60% of diagnosed Golden Retrievers. PRA2 results from a mutation in the TTC8 gene and accounts for 30% of Golden Retrievers diagnosed with PRA. Both mutations are autosomal recessive thus two copies of the same affected gene must be present for the disease to be observed and both males and females are equally affected. Presence of one copy of each affected genes in the same dog will not cause blindness. Clinical signs of PRA1 appear around 6 years of age. Clinical symptoms of PRA2 appear around 4 years of age. Breeding two carriers with the same mutation is predicted to produce 25% affected puppies and 50% carriers. Mating a carrier of PRA1 (that is N/N for PRA2) with a carrier of PRA2 (that is N/N for PRA1) will not produce affected animals.
Testing for PRA1 and 2 assists owners and breeders in identifying affected and carrier dogs. Breeders can use results from the tests as a tool for selection of mating pairs to avoid producing affected dogs. Genetic testing for PRA1 and 2 is recommended for Golden Retrievers and Golden Doodles. PRA2 has been reported at low frequency in Labrador Retrievers, but an extensive survey of the US population has yet to be investigated.